A Message From Paradigm Press

Below is an important message from one of our highly valued sponsors. Please read it carefully as they have some special information to share with you.

The next 34 days may be the most important of your life.

Because I believe, starting December 8th, Elon Musk will create 1,806,000 new millionaires over the coming years.

Will you be one of them?

That’s the decision you need to make today.

Hi, James Altucher here.

And I have compiled proof that Elon Musk plans to launch his biggest project yet.

The details are locked inside of a steel briefcase… A briefcase I will open and share with you at my Millionaire Maker Masterclass.

Elon Musk has worked tirelessly to keep this plan under wraps.

Because for the first time in his career, Elon is NOT trying to make headlines…

He’s trying to avoid them.

And the moment this hits the mainstream… it’s going to absolutely explode.

And there will be NO going back to the way life used to be.

Forget Paypal. Forget Tesla. Forget SpaceX. This will dwarf everything Elon has ever done before.

It’s bigger. It’s better. And I believe it will be the biggest wealth creation event in history.

Right now, only a small percentage of the world’s population knows what to expect.

Among them? A hedge fund titan… the world’s largest asset manager… a global hedge fund giant…

And after today, you.

This, right here, is a FREE MASTERCLASS where I help you get positioned to be one of Elon’s Next Millionaires.

Click here, and you’ll know everything there is to know about what Elon is planning…

You’ll understand why it could create the most wealth we have seen in human history…

You’ll have the proof that this is ALL coming to a head on December 8th…

And you’ll know exactly what to do over the next 34 days to become one of Elon’s next millionaires.

Imagine on December 8th…

Thinking back to THIS email.

Will it be the moment you made the single decision that could transform the rest of your life?

Or will it be your biggest regret?

That’s the choice in front of you today. And the best part - this masterclass is completely free to watch.

There’s zero risk to you. Just a few minutes of your time to see THE PROOF for yourself.

There's even a gift worth $1,000 waiting inside — only for a limited number of people who act fast today.

But first, a warning:

December 8th is quickly approaching — and this masterclass is for action takers only .

If that’s you, then click here now.

And welcome to the inside…

James Altucher

Editor, Altucher’s Investment Network

Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks

By Jessica Mitacek. Publication Date: 9/24/2026.

Shares of telehealth platform and direct-to-consumer (D2C) personal care products provider Hims & Hers Health (NYSE: HIMS) fell 6.7% on Wednesday, Sept. 23, as investors continued to weigh the fallout from August’s disappointing earnings report and mounting legal pressure, including a securities class action filed earlier this month and an ongoing FTC lawsuit over alleged privacy and billing practices.

Hims & Hers’ year-to-date (YTD) loss is over 12%, including a nearly 26% decline from its YTD high on July 6.

For shareholders who have already endured the stock’s elevated volatility this year, the ongoing legal scrutiny could further fuel a downtrend that has seen the stock shed more than 45% of its value over the past year.

Hims & Hers Faces FTC Lawsuit and Securities Class Action

On July 29, the U.S. Federal Trade Commission (FTC), the Utah Division of Consumer Protection and the Los Angeles County Counsel, on behalf of California, sued Hims & Hers in a joint federal lawsuit.

The lawsuit alleges that the company shared consumers’ sensitive health information with third-party advertising platforms, including Meta Platforms (NASDAQ: META) and Snap (NYSE: SNAP), despite promising to protect patient privacy.

According to the complaint, Hims & Hers made subscriptions difficult to cancel, routinely processed initial refill charges 10 days before consumers’ selected cadence and charged for prescriptions almost immediately after consumers submitted an intake form. This allegedly occurred despite the company telling consumers they could first consult with a medical provider to find a treatment that is "right for them."

Hims & Hers disputes the allegations and has said it intends to vigorously defend itself against the FTC’s claims.

Building on the FTC’s filing, a separate securities class action filed on Sept. 1 aims to represent Hims & Hers shareholders who purchased or acquired the company’s securities between Aug. 4, 2025, and July 29, 2026.

The class action cites many of the same alleged privacy and billing practices described in the FTC case. It further contends that Hims & Hers and certain executives violated the Securities Exchange Act of 1934 by making materially misleading statements about the company’s business, operations and prospects, while failing to disclose that those practices could expose the company to regulatory scrutinyand potential financial penalties.

Investors seeking appointment as lead plaintiff in the class action have until Nov. 2, 2026, to file a motion with the court, according to Robbins Geller Rudman & Dowd LLP, a securities-fraud law firm publicizing the class action.

Legal Setbacks, Earnings Misses Cloud Hims & Hers’ Outlook

The FTC and class-action lawsuits are among the latest in a series of headwinds facing the D2C healthcare company. Between those two legal setbacks, Hims & Hers reported a Q2 earnings miss on Aug. 10, its second consecutive miss and fourth in the past five quarters.

Despite strong subscriber growth and 38% year-over-year (YOY) revenue growth, the Q2 report contained numerous areas of concern. Q2 earnings per share (EPS) of negative 37 cents missed analyst expectations of negative five cents and marked a significant YOY decline from Q2 2025’s EPS of 17 cents.

Hims & Hers reported a net loss of $86.3 million in Q2, a concerning reversal from net income of $42.5 million in the same quarter a year earlier. Meanwhile, adjusted gross margin fell to 64%, down approximately six percentage points quarter over quarter.

The company’s Q2 report did provide some positive takeaways, though they came with caveats. Hims & Hers expanded access to branded GLP-1 weight-loss products, while international revenue—driven by the acquisition of Eucalyptus earlier in 2026—grew.

However, Q2 free cash flow was negative $68 million, and Hims & Hers recorded roughly $81 million in acquisition, restructuring and FTC-related legal costs. With the FTC case still pending and the securities class action now underway, legal expenses could remain a headwind.

Revenue and Subscriber Growth Offer a Silver Lining

In Q2, Hims & Hers saw an acceleration in both top-line and subscriber growth.

Revenue of $753.21 million exceeded analyst expectations of $698.9 million, representing a more than 38% YOY increase. Management also raised full-year 2026 revenue guidance to a range of $3.1 billion to $3.3 billion.

The company gained roughly 300,000 new subscribers, bringing its total to nearly 3 million. Additionally, Hims & Hers’ investment in AI is beginning to bear fruit. The company reported early benefits from its AI-native care platform, including a threefold increase in customer messaging, an approximately 50% reduction in nonclinical support tasks and lower cancellation rates in pilot cohorts. Management expects AI investments to pay back within 12–18 months and support improved retention and cost efficiency.

Still, Wall Street’s expectations appear to be tempered. Of the 16 analysts currently covering the stock, only three assign it a Buy rating. Overall, HIMS receives a consensus Hold rating, alongside a 12-month price target that implies around 13% potential upside.

But with a beta of 2.42, the stock is 142% more volatile than the broad market, which has kept it in favor with bearish traders. Current short interest is 26.69%, or nearly 55 million shares out of more than 233 million shares outstanding. As the company continues to grapple with earnings disappointments and costly legal pressure, investors should expect ongoing volatility.